Skin rashes, vomiting, and seizures: Wheat Belly followers share their re-exposure experiences
When you have eliminated wheat and grains from your life, odd things happen when you get re-exposed. First of all, you’ve lost the partial–partial, never total–tolerance to some of the adverse effects of wheat and grains, and they come back with a vengeance upon re-exposure. And it’s not just due to the “gluten.” Those of you hanging around here understand that there is far more to wheat and grains than gluten, such as reactions to the bowel toxicity of wheat germ agglutinin, or the mind “fog” of gliadin-derived opiate peptides, or allergic reactions to alpha amylase inhibitors. And the reactions can be really strange, sometimes even dangerous or life-threatening. The reactions are as varied as the people who have them. To illustrate, I recently asked the Wheat Belly Facebook audience to share their wheat/grain re-exposure experiences. You will appreciate that there is nothing “indulgent” about a re-exposure, no more than a facial rash, joint pain, or diarrhea are causes for celebration. Stop eating cucumbers for a year, then have a cucumber salad: nothing happens with re-exposure. Banish eggs from your diet, then have an omelet: nothing happens. But try this with wheat and grains, and all hell can break loose. Read the comments and it quickly becomes clear that wheat/grain re-exposure is a really, really bad idea. Here are some of the responses that flooded in within hours: Amelia: “The day after I’ve ...
Publication date: November–December 2020Source: Heart &Lung, Volume 49, Issue 6Author(s): Linda Clements, Susan K. Frazier, Debra K. Moser, Terry A. Lennie, Misook L. Chung
Publication date: 1 January 2021Source: Personality and Individual Differences, Volume 168Author(s): Feizhong Zheng, Wenting Wu, Lijing Wang, Arlette J. Ngoubene-Atioky, Li Chen
Publication date: Available online 22 September 2020Source: International Journal of PsychophysiologyAuthor(s): Chiara Massullo, Giuseppe Alessio Carbone, Benedetto Farina, Angelo Panno, Cristina Capriotti, Marta Giacchini, Sérgio Machado, Henning Budde, Eric Murillo-Rodríguez, Claudio Imperatori
CONCLUSION: In a NHP ARS model, sargramostim administered starting at 48 h post-radiation was effective to improve survival, while beneficial hematological effects were observed with sargramostim initiated up to 120 h post exposure. PMID: 32960660 [PubMed - as supplied by publisher]
CONCLUSIONS: Under a real-life clinical practice setting, SSTS provides effective pain management and is easy to use for patients and nurses. PMID: 32959632 [PubMed - as supplied by publisher]
In 2019, before the pandemic hit, nearly 1 in 5 adults had depression and nearly 1 in 6 had anxiety, with dramatic increases seen in 2020.Medscape Medical News
Authors: Wong A, Keith C, Gregory H, Liew D Abstract COVID-19 brings with it unprecedented challenges in clinical management. An important component of care is the provision of safe and effective symptom control. Given the emerging literature reporting on the risk of QT prolongation and arrhythmias associated with COVID-19 disease and experimental therapies, we highlight some considerations for the prescribing of palliative care medications in this context. Based on the experience gained from palliative care referrals at our institution prior to and during the COVID-19 pandemic, and in collaboration with our clinic...
We report a case of using ketamine as a patient-controlled analgesia (PCA) for the treatment of CPS. A 58-year-old male with CPS presented with severe generalized body pain refractory to multiple pharmacological interventions. He was started on a basal infusion rate at 0.3 mg/kg/h with a ketamine PCA bolus of 10 mg with a 10-minute lockout period. Over the next 7 days, the basal infusion rate was titrated up to 2.1 mg/kg/h relative to the number of times the patient pressed the PCA. At the end of the trial, the patient reported 0/10 pain with lightheadedness on the first day being the only side ...
Publication date: November 2020Source: Epilepsy &Behavior, Volume 112Author(s): Mehri Salari, Masoud Etemadifar, Koroush Gharagozli, Koorosh Etemad, Farzad Ashrafi, Helia Ashourizadeh
Publication date: November 2020Source: Epilepsy &Behavior, Volume 112Author(s): Daniel Delev, Karlijn Hakvoort, Alexander Grote, Georg Neuloh, Hans Clusmann, Marec von Lehe
More News: Acid Reflux | Acne | Allergy & Immunology | Anxiety | Ataxia | Babies | Babies Heart Conditions | Back Pain | Blogging | Cardiology | Celiac Disease | Chronic Pain | Coeliac Disease | Depression | Eczema | Eyes | Gastroenterology | Gastroesophageal Reflux Disease | GERD | Gluten | Hangovers | Headache | Heart | Heartburn | Hives | Insomnia | Itchiness | Men | Middle East Health | Migraine | Nutrition | Pain | Pericarditis | Psoriasis | Skin | Sleep Disorders | Sleep Medicine | Sports Medicine | Suicide | Toxicology | Urology & Nephrology | Ventricular Tachycardia | Wheat